News | October 25, 2024
Jagsonpal Pharmaceuticals Q2 FY25 net profit up at Rs. 11.45 Cr
Jagsonpal Pharmaceuticals has reported total income of Rs. 76.34 crores during the period ended September 30, 2024
Jagsonpal Pharmaceuticals has reported total income of Rs. 76.34 crores during the period ended September 30, 2024
Solara Active Pharma Sciences has reported total income of Rs. 347.27 crores during the period ended September 30, 2024
Company receives acceptability, in principle, for ZyVac TCV making it eligible for purchase by United Nations procurement agencies
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
ActivShield technology is a portable, novel sterilization modality that does not require conventional infrastructure
This partnership will enable healthcare organizations to provide best-in-class patient/consumer experiences
The proceeds from its fresh issuance to the extent of Rs 107 crore will be utilized for funding the capital expenditure requirements
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
Diltiazem Hydrochloride Extended-Release Capsules USP are indicated for the treatment of hypertension
Fludrocortisone acetate tablets will be produced at the Group's manufacturing site at Moraiya, Ahmedabad
Subscribe To Our Newsletter & Stay Updated
